News for Innovent Biologics, Inc. (6IB.F)

Published at

Mar 3, 2021 4:12 AM

by thestreet.com

positive

positive

CMAB Biopharma Congratulates Partner Innovent Biologics On FDA Clearance Of IND Application Of Its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on

6IB.F 6IB.BE 1801.HK

Read more →
Published at

Mar 3, 2021 4:12 AM

by markets.businessinsider.com

positive

positive

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ('CMAB') congratulates its partner Innovent Biologics, Inc ('Innovent') (...

IVBXF 6IB.F 6IB.BE 1801.HK

Read more →
Published at

Mar 3, 2021 4:12 AM

by prnewswire.com

neutral

neutral

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

/PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug...

6IB.F 6IB.BE 1801.HK

Read more →
Published at

Mar 1, 2021 1:00 AM

by thestreet.com

mixed

mixed

Innovent Announces First Patient Outside China Dosed In The Phase 1 Clinical Trial Of Anti-CD47/PD-L1 Bispecific Antibody

SAN FRANCISCO and SUZHOU, China, Feb. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company

IVBXF 6IB.F 6IB.BE 1801.HK LLY.BE

Read more →
Published at

Mar 1, 2021 1:00 AM

by prnewswire.com

positive

positive

Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

IVBXF 6IB.F 1801.HK

Read more →
Published at

Feb 23, 2021 2:22 AM

by markets.businessinsider.com

mixed

mixed

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical ...

IVBXF 6IB.F 6IB.BE 1801.HK LLY.BE

Read more →
Published at

Feb 23, 2021 2:22 AM

by markets.businessinsider.com

mixed

mixed

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Feb. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical ...

IVBXF 6IB.F 6IB.BE 1801.HK LLY.BE

Read more →
Published at

Feb 9, 2021 1:00 AM

by prnewswire.com

neutral

neutral

Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

IVBXF 6IB.F 6IB.BE 1801.HK

Read more →
Published at

Feb 3, 2021 5:30 AM

by markets.businessinsider.com

mixed

mixed

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-S...

SAN FRANCISCO and SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical c...

1900.HK LLY IVBXF 6IB.F 6IB.BE 1801.HK

Read more →
Published at

Feb 3, 2021 5:30 AM

by markets.businessinsider.com

mixed

mixed

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-S...

SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical c...

1900.HK LLY IVBXF 6IB.F 6IB.BE 1801.HK

Read more →
Published at

Jan 25, 2021 12:25 PM

by benzinga.com

mixed

mixed

Report 2021, Central Nervous System Treatment Market Size, Share, Growth, Trends, Analysis, Revenue, Forecast Report – 2020-2027

Pune, India, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is expected to gain momentum in the forthcoming ...

IVBXF CDI 6IB.F 6IB.BE 1801.HK TEVAN.MX TEVA TEV.F NVSN.MX NVSEF NVS NOVN.SW NOTA.MU NOTA.F NOTA.BE MRK.PA MRK.MX MRK 6MK.MU 6MK.F 6MK.DE 6MK.BE

Read more →